Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer.


Journal

Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519

Informations de publication

Date de publication:
May 2020
Historique:
pubmed: 28 3 2020
medline: 28 3 2020
entrez: 28 3 2020
Statut: ppublish

Résumé

In the original publication of the article the author has found few incorrect values in the Table 1.

Identifiants

pubmed: 32215699
doi: 10.1007/s00280-020-04056-6
pii: 10.1007/s00280-020-04056-6
pmc: PMC7645457
doi:

Types de publication

Published Erratum

Langues

eng

Sous-ensembles de citation

IM

Pagination

1009-1010

Commentaires et corrections

Type : ErratumFor

Auteurs

Hani M Babiker (HM)

University of Arizona Comprehensive Cancer Center, Tucson, AZ, USA. hanibabiker@email.arizona.edu.

Mohammed Milhem (M)

University of Iowa Hospital, Iowa City, IA, USA.

Joseph Aisner (J)

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

William Edenfield (W)

Greenville Health System, Greenville, SC, USA.

Dale Shepard (D)

Cleveland Clinic, Cleveland, OH, USA.

Michael Savona (M)

Vanderbilt University Medical Center, Nashville, TN, USA.

Swaminathan Iyer (S)

MD Anderson Cancer Center, Houston, TX, USA.

Maen Abdelrahim (M)

Houston Methodist Hospital, Houston, TX, USA.

C L Beach (CL)

Celgene Corporation, Summit, NJ, USA.

Barry Skikne (B)

Celgene Corporation, Summit, NJ, USA.
University of Kansas Medical Center, Kansas City, KS, USA.

Eric Laille (E)

Celgene Corporation, Summit, NJ, USA.

Kao-Tai Tsai (KT)

Celgene Corporation, Summit, NJ, USA.

Thai Ho (T)

Mayo Clinic, Phoenix, AZ, USA.

Classifications MeSH